Navigation Links
Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
Date:10/8/2008

fluenza vaccine generated broader, more balanced antibody responses than unformulated vaccine, and also generated influenza-specific T-cell responses. Adjusting the ratio of Vaxfectin(R) to vaccine drove substantial increases in either antibody or T-cell responses, without reducing the other type of response, compared with unformulated vaccine. The ability to favor primarily antibody or T-cell responses could provide important advantages in developing vaccines for specific applications.

H5N1 Pandemic Influenza Vaccine Phase 1 Trial Update

Vical reported in July that the company's Vaxfectin(R)-formulated H5N1 pandemic influenza DNA vaccines achieved potentially protective levels of antibody responses (H5 hemagglutination inhibition, or HI, titers of at least 40 and at least a four-fold increase from baseline) in at least 50% and up to 67% of evaluable subjects in the higher dose cohorts in a 100-subject Phase 1 trial.

Following injections at Days 0 and 21, responses peaked by Day 56, and more than 90% of the responders had sustained responses through the last measurement (Day 84) at the time of the preliminary analysis. Expanded data presented today shows that in the two cohorts receiving the highest H5 DNA dose (1 mg), 80% to 100% of the responders had sustained responses through Day 182. Similar results for a vaccine deployed during the early stages of a pandemic outbreak could provide substantial protection to the at-risk population and potentially alter the course of the pandemic.

These results support further development of Vaxfectin(R)-formulated DNA vaccines, and could position them as potential alternatives to conventional vaccines. DNA vaccines are fundamentally different from conventional vaccines because they do not contain any part of the virus itself, and may offer compelling advantages in response to a pandemic outbreak because of significantly reduced development and manufacturing times. Vical is currently seeking funding to
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
2. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
3. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
4. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
5. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
6. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
7. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
8. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Future Prospects for Companies in Antihistamines, Corticosteroids, ... - new study showing you trends, partnerships, and ... allergic rhinitis drugs heading? What are the commercial prospects ... you potential revenues and other trends to 2025, discussing ... report provides 273 tables, charts, and graphs. Discover the ...
(Date:9/4/2015)... , Sep. 04, 2015 ... of the "Investigation Report on China,s Sodium Ibandronate Market, ... and used in the clinic under the trade name of ... Austria in 1996, sodium ibandronate was approved by ... treatment of osteoporosis under the trade name of Boniva. However, ...
(Date:9/4/2015)... September 4, 2015 Hutchison ... that Hutchison MediPharma Limited ("HMP"), its drug R&D ... second proof-of-concept ("POC") trial of fruquintinib in patients ... in China .  The top-line ... meeting the primary efficacy endpoint of progression free ...
Breaking Medicine Technology:Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Investigation Report on China's Sodium Ibandronate Market 2010-2019 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3
... Late Stage Clinical Therapeutic Cancer... -- TUEBINGEN, Germany, September 21, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Inc., today announced that it reported positive preclinical ... Association for the Study of Diabetes (EASD).  CCX140, ... the chemokine receptor CCR2, improved metabolic function while ... in an animal model, and was well tolerated ...
Cached Medicine Technology:immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 2immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 3immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 4immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 5immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 6immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 7immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 8immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 9immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 10ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 2ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 3ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 4
(Date:9/4/2015)... ... September 04, 2015 , ... “Getting away from the daily stressors ... explore, revitalize and strengthen their ‘couple-ness,’” says Jean Claude Wietzel, general manager at ... Resort Maui, the island’s only Forbes Five Star resort and Travel + Leisure’s No. ...
(Date:9/4/2015)... ... ... for a quick and convenient way to produce a hot remedy for colds. The K ... and simple way to brew a hot cup of cold remedy when desired. In doing ... comfort and health. The invention features a novel design that is lightweight, compact and portable. ...
(Date:9/4/2015)... Angeles, CA (PRWEB) , ... September 04, 2015 , ... ... Program was ranked number 9 nationwide by Doximity. Faculty, residents and staff ... we take great pride in the quality of our ophthalmology residency program. Our faculty ...
(Date:9/4/2015)... ... September 04, 2015 , ... Having access to a doctor ... to an increasing amount of unnecessary emergency room visits which affects hospitals’ abilities to ... country’s health bill. Fortunately, a solution to alleviate this problem has recently presented itself, ...
(Date:9/4/2015)... New York, NY (PRWEB) , ... September 04, 2015 , ... ... 400 meters qualifying heat, and followed up with victory in the men’s 400 meters ... Caribbean (NACAC) Senior Track and Field Championships in San Jose, Costa Rica in August ...
Breaking Medicine News(10 mins):Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 3Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3
... INDIANAPOLIS, Nov. 16 Standard Management,Corporation ("Standard ... an Indianapolis-based company, provides through Universal Healthcare,Company, ... long-term care,and infusion therapy sector of the ... definitive stock purchase agreement to sell its ...
... Calls upon State Regulators to Impose Stiffer Penalties, ... License for Lying to State Investigators, CLAREMONT, ... yesterday filed a class action lawsuit against Health ... practice of,retroactively canceling health insurance policies has needlessly ...
... Ohio, Nov. 16 Robbins & Myers, Inc.,(NYSE: ... the Bear Stearns,3rd Annual Commodities and Capital Goods Conference ... Wallace, President and Chief Executive Officer,and Christopher M. Hix, ... the Company. The Company,s presentation is set for ...
... factors at six sites nationwide , FRIDAY, Nov. ... at the genetic and environmental factors that may cause ... enrolling 2,700 children and their families from six areas ... Early Development -- which researchers called the largest of ...
... Four Small Holes Between Ribs ... After 1 1/2 Days, TYLER, Texas, Nov. 16 ... is the first in east,Texas to benefit from a heart ... System. Mr. Roden was released from the,hospital just 1 1/2 ...
... to the,recently released follow-up study to the ... the August issue of the,Journal of the ... children and young people with AD/HD who ... with behavioral management and,educational adaptations fared better ...
Cached Medicine News:Health News:Standard Management Signs Stock and Real Estate Purchase Agreement 2Health News:Health Net Hit With Class Action Alleging Unfair Business Practices Over Retroactive Cancellations of Health Insurance Policies 2Health News:Health Net Hit With Class Action Alleging Unfair Business Practices Over Retroactive Cancellations of Health Insurance Policies 3Health News:Major U.S. Autism Study Gets Under Way 2Health News:Video: Patient at Mother Frances Receives Heart Bypass Without Opening Chest 2
... Ventilates and removes chemical fumes, ... exhaust. Bonded charcoal filters remove ... ensure safe exhaust flow speed ... access opening. Includes air speed ...
This modular benchtop fume hood ventilates and purifies chemical fumes, allowing safe indoor release of exhaust. Bonded charcoal filters remove most organic contaminants. Options include final HEPA f...
... fume hood is the same ... includes a flat internal baffle ... shell. The baffle slopes forward, ... flow to sweep the deck ...
This fume hood features a one-piece shell molded of polyethylene with a clear acrylic panel that slides on inside tracks. It can be set in an open, closed or intermediate position....
Medicine Products: